Filing Details

Accession Number:
0001209191-21-014517
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-25 20:23:35
Reporting Period:
2021-02-23
Accepted Time:
2021-02-25 20:23:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348911 Kalvista Pharmaceuticals Inc. KALV Pharmaceutical Preparations (2834) 200915291
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1366244 L Benjamin Palleiko C/O Kalvista Pharmaceuticals, Inc.
55 Cambridge Parkway, Suite 901E
Cambridge MA 02142
Cfo, Cbo & Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-23 29,642 $6.74 94,642 No 4 M Direct
Common Stock Disposition 2021-02-23 1,000 $35.40 93,642 No 4 S Direct
Common Stock Disposition 2021-02-23 22,093 $33.73 71,549 No 4 S Direct
Common Stock Disposition 2021-02-23 5,293 $33.06 66,256 No 4 S Direct
Common Stock Disposition 2021-02-23 1,256 $31.77 65,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-02-23 29,642 $0.00 29,642 $6.74
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
29,611 2026-12-28 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.34 to $35.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $34.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.67 to $33.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.43 to $32.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  6. The option is fully vested.